LIVN vs NPCE
LIVN: LivaNova is a medical device company specializing in advanced therapies for cardiac surgery and neurological disorders, including epilepsy and sleep apnea. NPCE: NeuroPace is a medical device company providing the first brain-responsive neuromodulation system that treats drug-resistant epilepsy by delivering personalized, real-time therapy at the seizure source.
Side-by-side fundamentals
| Metric | LIVN | NPCE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $75.91 | $12.39 | |
| Market cap | $4.2B | $425M | |
| P/E as of 2026-10-08 | 22.46 | n/a | |
| Net margin FY2025, SEC XBRL | -17.5% | -21.5% | LIVN higher |
| Gross margin FY2025, SEC XBRL | +67.7% | +77.2% | NPCE higher |
| Operating margin FY2025, SEC XBRL | +14.4% | -16.3% | LIVN higher |
| ROE FY2025, SEC XBRL | -20.2% | -112.8% | LIVN higher |
| ROA FY2025, SEC XBRL | -9.3% | -20.3% | LIVN higher |
| Debt / equity as of 2026-09-03 | 0.22 | 4.08 | LIVN lower |
| Revenue growth (YoY) as of 2026-09-03 | +12.4% | +18.1% | NPCE higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +30.0% | NPCE higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.95 | 1.13 | |
| 1-year return as of 2026-10-08 close | +42.2% | +11.3% | LIVN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.